The median for vaccinia-specific neutralizing antibody ID50 values for all those subjects was 133 (IQR, 79-206) [7]. of contributing genes and polymorphisms, are underway. Keywords:GWAS, Smallpox Vaccine, Vaccinia Computer virus, Humoral Immunity, Immunogenetics, SNPs == Introduction == Acrizanib Vaccination is the only defense against smallpox (variola major), an infectious disease with approximately a 30% mortality rate [1]. Despite eradication, the disease is feared as a potential agent of bioterrorism because of its lethality, transmissibility, and the lack of known treatment [2]. Therefore, immunity to smallpox after vaccination is an important issue for biodefense and for advancing our understanding of the immunogenetic regulation of the immune response. Immune Acrizanib response to smallpox vaccination can be highly variable among individuals. Genetic variations influence adaptive immune responses and play important roles in defining the type of host response generated by a vaccine. Associations between gene polymorphisms (SNPs) and variations in adaptive immune responses to smallpox vaccine are poorly understood. Closer study of the individual immune and genetic factors related to vaccinia virus-induced immunity is needed. Smallpox vaccine (live vaccinia computer virus) has one of the highest complication rates among all the vaccines currently in use [3]. Previous studies of genetic predisposition for local and systemic adverse events (mostly fever) following primary smallpox vaccination revealed genetic variants (specific haplotypes in theIL1andIL18genes) associated with these adverse events [4]. Further, associations between adverse events (i.e., fever) after Acrizanib smallpox vaccine and polymorphisms in the 5,10-methylenetetrahydrofolate reductase (MTHFR), interferon regulatory factor-1 (IRF1), andIL4genes were found in two independent studies [5]. Host genetics has been demonstrated to play a role in Acrizanib the variation in vaccine-induced immunity [6]. A number of human leukocyte antigen (HLA) alleles have been recently found to play a role in smallpox vaccine-induced immunity [7]. For example, B*4403 and B*4801 alleles are associated with lower neutralizing antibody titers, whereas alleles DQB1*0302 and DQB1*0604 are linked to higherantibody titersin individuals immunized with smallpox vaccine [7]. Another example is the association found between individual SNPs and haplotypes in the genes coding forIL18andIL18R1and vaccinia antibody titers [8]. These genetic associations were discovered using a candidate-gene approach. Genome-wide association studies (GWAS), including population-based vaccination studies, are a powerful approach for discovery of novel genetic variants and links with immunity [9;10]. To identify additional host genetic factors associated with variations in humoral immune response to smallpox vaccine, we conducted a GWAS of smallpox vaccine in African-American, Splenopentin Acetate Caucasian, and Hispanic populace samples and examined the association between SNPs and post-vaccination antibody titers. We hypothesized that other genes, beside HLA, cytokine, and cytokine receptor genes, may also be associated with smallpox vaccine-induced humoral immunity. == Materials and Methods == == Study subjects == Acrizanib As previously described, our study cohort comprised a sample of 1 1,076 healthy subjects (age 18 to 40 years) who participated in both the US Department of Health and Human Services civilian healthcare worker smallpox immunization program at Mayo Clinic in Rochester, MN, and the smallpox immunization program at the US Naval Health Research Center (NHRC) in San Diego, CA [7;8;11]. Out of 1 1,076 subjects, 1,071 subjects had vaccinia neutralizing antibody and genotyping data available for this report. All study subjects received a single dose of live computer virus Dryvax vaccine (Wyeth Laboratories) at least one month, but no more than four years, earlier.
